AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00882050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study NCT01042093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toradol
Description: Toradol 30mg/ml (1 ml)
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: -Baseline and no more frequently than every 6 months until death
Study NCT01042093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Activities of Daily Living Questionnaire
Description: * 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Instrumental Activities of Daily Living, subscale of the OARS
Description: * 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death
Study NCT00115167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q4W
Study NCT00115167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Q4W
Study NCT00141271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geodon (Ziprasidone)
Description: Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
Study NCT00141271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geodon (Ziprasidone)
Description: Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
Study NCT00141271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
Study NCT00805441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY686017
Description: 50 milligrams (mg) daily by oral route for 12 weeks
Study NCT00805441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily by oral route for 12 weeks
Study NCT04917315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2002 A mg
Description: administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
Study NCT04917315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
Study NCT00629564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg oral
Study NCT00629564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 15 minute intravenous infusion
Study NCT00631202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
Study NCT03717233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
Study NCT04382053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
Study NCT04382053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study NCT04382053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study NCT04623996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0184
Description: Oral dose
Study NCT01959009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
Study NCT00977678 — intervention group
Intervention type: OTHER
Intervention: open access gastroscopy
Description: access to gastroscopy without preceding appointment
Study NCT00977678 — intervention group
Intervention type: OTHER
Intervention: Gastroscopy by appointment
Description: Gastroscopy after preceding appointment in a conventional outpatient clinic
Study NCT00924833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet BID
Study NCT00924833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 25 mg tablets. One tablet twice daily.
Study NCT00924833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
Study NCT03584282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
Study NCT03584282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
Study NCT02411188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The STEP Program
Description: Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
Study NCT00587405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy.
Study NCT00587405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation
Description: As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
Study NCT00759993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chromium piccolinate
Description: 1000mg tab
Study NCT00759993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for chromium piccolinate
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Karnofsky Self-reported Performance Rating Scale
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Number of Falls
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death
Study NCT06723847 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic pancreaticoduodenectomy
Description: All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
Study NCT01042093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1 mg/ml (0.5 ml)
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Physical Health Section, subscale of the OARS
Description: * 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death
Study NCT00501995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
Study NCT00102622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraperitoneal tgDCC-E1A
Description: Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: MOS Social Activity Survey
Description: * 4 items about social activity~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Unintentional Weight Loss
Description: * 2 items about nutrition~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: GENETIC
Intervention: Peripheral Blood Draw
Description: -Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: GENETIC
Intervention: Buccal Swab
Description: * Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death
Study NCT02513407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Attend healthy nutritional education session
Study NCT02513407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Attend healthy nutritional education session
Study NCT02513407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend EML educational session
Study NCT02513407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend exercise educational session
Study NCT02513407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive fitness tracker
Study NCT02513407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02513407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02513407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02513407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Follow geriatric assessment-driven treatment plan
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01630330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Atrial Fibrillation Ablation with SmartTouch catheter
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Heart Health and Smoking History from BRFSS questionnaire
Description: * 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death
Study NCT00102622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
Study NCT00102622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
Study NCT03591042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical length screening
Description: transvaginal ultrasound cervical length
Study NCT01630330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Atrial Fibrillation Ablation with SmartTouch catheter
Study NCT02804074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimization of antihypertensive treatment based on office BP
Description: Optimization of antihypertensive treatment based on office BP
Study NCT02804074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of antihypertensive treatment based on 24-hour ABPM
Description: Optimization of antihypertensive treatment based on 24-hour ABPM
Study NCT03998956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: Circumferential PV isolation only
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02517034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03090646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Up to three gift cards to a major online retailer.
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Gait Speed
Description: * Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Grip Strength
Description: * Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Height and Weight measurements
Description: -Baseline and no more frequently than every 6 months until death
Study NCT00004888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT00004888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00004888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00004888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03340337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo-Russian
Description: Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.
Study NCT03340337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aussie
Description: Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.
Study NCT03340337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RBS
Description: Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.
Study NCT02579265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid 20% (investigational lipid for parenteral nutrition)
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein.
Study NCT02088801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq, blade without channel for tracheal tube intubation
Description: Intubation
Study NCT02088801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KingVision , blade without channel for tracheal tube intubation
Study NCT02088801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A.P. Advance, blade without channel for tracheal tube intubation
Study NCT02088801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Study NCT02043704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Details covered in arm description.
Study NCT02043704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Acetaminophen
Description: Details covered in arm description.
Study NCT02604563 — intervention group
Intervention type: OTHER
Intervention: Blood pressure measurement
Description: -Baseline and no more frequently than every 6 months until death
Study NCT02604563 — intervention group
Intervention type: PROCEDURE
Intervention: Optional bone marrow biopsy
Description: -1 optional bone marrow biopsy
Study NCT02604563 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw for trauma measurements
Description: -For Arm E only
Study NCT04558372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
Study NCT04558372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.